Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical Trial Basics

    ... the new study treatment, the standard treatment, or a placebo . Clinical trials may compare a new medical approach to a standard one that is already available or to a placebo that contains no active ingredients or to no intervention. Some ...

    Page last updated 01/20/2015 - 4:58pm.

  2. Clinical Trial Basics

    ... the new study treatment, the standard treatment, or a placebo . Clinical trials may compare a new medical approach to a standard one that is already available or to a placebo that contains no active ingredients or to no intervention. Some ...

    Page last updated 01/20/2015 - 4:46pm.

  3. ASH 2012 - Reviewing MDS Progress from Research and Clinical Perspectives

    ... in the romiplostin group and the group treated with a placebo . In other words, with additional follow-up, there actually did not ...

    Interview last updated 02/07/2013 - 1:28pm.

  4. Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

    ... or subcutaneously x 7 days every 4 weeks Drug: Placebo (for 33A) Placebo supplied in single-use vials matching 33A ...

    Clinical Trial last updated 04/29/2016 - 12:55pm.

  5. Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

    ... or withdrawal of consent, or lack of response. Drug: Placebo Matching Placebo to Imetelstat will be administered. ...

    Clinical Trial last updated 04/20/2016 - 3:39pm.

  6. Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

    ... IM Other Name: CMV-MVA Triplex Vaccine Other: Placebo Given IM Other Names: placebo therapy PLCB sham therapy ...

    Clinical Trial last updated 04/29/2016 - 11:00am.

  7. Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

    ... Biological: CMVpp65-A*0201 peptide vaccine Given SC Other: Placebo Given SC Other Name: PLCB Other: Laboratory Biomarker ...

    Clinical Trial last updated 04/29/2016 - 2:03pm.

  8. Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission (QUAZAR AML-001)

    ... Drug: 300 mg Oral Azacitidine Maintenance therapy Drug: Placebo ...

    Clinical Trial last updated 04/29/2016 - 8:39am.